Significant hyperglycemia is commonly observed immediately after solid organ and bone marrow transplant as well as with subsequent hospitalizations. Surgery and procedures are well known to cause pain and stress leading to secretion of cytokines and other hormones known to aggravate insulin action. Immunosuppression required for transplant and preexisting risk are also major factors. Glucose control improves outcomes for all hospitalized patients, including transplant patients, but is often more challenging to achieve because of frequent and sometimes unpredictable changes in immunosuppression doses, renal function, and nutrition. As a result, risk of hypoglycemia can be greater in this patient group when trying to achieve glucose control goals for hospitalized patients. Key to successful management of hyperglycemia is regular communication between the members of the care team as well as anticipating and rapidly implementing a new treatment paradigm in response to changes in immunosuppression, nutrition, renal function, or evidence of changing insulin resistance.

Original languageEnglish (US)
JournalCurrent diabetes reports
Issue number4
StatePublished - Apr 2015


  • Bone marrow transplant
  • Diabetes complication
  • Diabetes mellitus type 1
  • Diabetes mellitus type 2
  • Heart transplant
  • Hyperglycemia
  • Kidney transplant
  • Organ transplant
  • Rejection

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Management of the Hospitalized Transplant Patient'. Together they form a unique fingerprint.

Cite this